---
title: "CKLIFE SCIENCES showcased its research and development results on tumor growth inhibition at the annual meeting of the Cancer Immunotherapy Society"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265441983.md"
description: "CKLIFE SCIENCES showcased its therapeutic cancer vaccine research results at the Society for Immunotherapy of Cancer (SITC) 2025 meeting in Maryland, USA. The progress of vaccines targeting TROP2, PRAME, and PD-L1 was highlighted, demonstrating potential in inhibiting tumor growth. Notably, the vaccine targeting TROP2 achieved an 80% inhibition rate in colorectal cancer and complete inhibition in breast cancer. The vaccines targeting PD-L1 and PRAME showed an inhibition rate exceeding 95% in lung cancer models. The company plans to advance these candidate vaccines to the clinical trial stage"
datetime: "2025-11-12T04:59:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265441983.md)
  - [en](https://longbridge.com/en/news/265441983.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265441983.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/265441983.md) | [繁體中文](https://longbridge.com/zh-HK/news/265441983.md)


# CKLIFE SCIENCES showcased its research and development results on tumor growth inhibition at the annual meeting of the Cancer Immunotherapy Society

CKLIFE SCIENCES (00775.HK) successfully held the Society for Immunotherapy of Cancer (SITC) 2025 conference in National Harbor, Maryland, USA, where it presented preclinical research data on the development of therapeutic cancer vaccines. The focus was on significant progress in the development of cancer vaccines targeting trophoblast cell surface antigen 2 (TROP2), preferentially expressed antigen in melanoma (PRAME), and programmed cell death ligand 1 (PD-L1), showcasing their potential to inhibit tumor growth.

The research team at CKLIFE SCIENCES disclosed two innovative vaccines targeting the TROP2 protein. Results showed that the vaccines effectively stimulated T cells against TROP2, with the protein vaccine achieving an 80% tumor growth inhibition rate in colorectal cancer and completely (100%) inhibiting breast cancer growth.

CKLIFE SCIENCES also announced the development results of innovative vaccines that can simultaneously target both PD-L1 and PRAME, demonstrating over 95% tumor growth inhibition in a preventive lung cancer model after vaccination. Furthermore, the vaccines maintained their defensive capability against tumor rechallenge tests three months post-vaccination, reflecting the ability to induce lasting immune memory.

Dr. Du Jianming, Vice President and Chief Scientific Officer of CKLIFE SCIENCES, stated that the results of the cancer candidate vaccines targeting TROP2 and PRAME/PD-L1 are encouraging and are expected to accelerate the development process of effective therapeutic cancer vaccines. The current goal is to advance these candidate vaccines to the clinical trial stage

### Related Stocks

- [CKLIFE SCIENCES (00775.HK)](https://longbridge.com/en/quote/00775.HK.md)

## Related News & Research

- [WuXi XDC Cayman, Inc. (2268) Receives a Buy from Orient Securities](https://longbridge.com/en/news/280931364.md)
- [Henlius Wins Key EMA Backing for Cancer Drug Serplulimab in Europe](https://longbridge.com/en/news/280997570.md)
- [HKTVmall parent firm under fire for testing how long animal heads can survive](https://longbridge.com/en/news/281327412.md)
- [Medtide (SEHK:3880) Net Margin Surge In 1H FY 2025 Tests Earnings Quality Concerns](https://longbridge.com/en/news/281199919.md)
- [WuXi XDC Cayman Inc. completed the acquisition of 60% stake in BioDlink International Company Limited from a group of shareholders.](https://longbridge.com/en/news/281227787.md)